Most side effects depend on the dose used. The incidence of side effects and their severity are most pronounced at the beginning of treatment and decrease as therapy continues.
Information on the incidence of side effects is presented on the basis of literature data and spontaneous reports.The frequency is indicated as: very often (> or = 1/10), often (from> or = 1/100 to <1/10), infrequently (from 1/1000 to <1/100), rarely (> or = 1 / 10000 to <1/1000), very rarely (<1/10000), or unknown (can not be estimated based on existing data).
From the nervous system:
very often - drowsiness, dizziness
often - dystonia, headache;
infrequently - tardive dyskinesia, parkinsonism, convulsions, akathisia;
very rarely - malignant neuroleptic syndrome.
From the side of mental activity:
often - insomnia, nervousness, agitation, decreased libido.
From the cardiovascular system:
often - tachycardia, palpitations;
infrequently - hypotension, hot flashes;
rarely - prolongation of the QT interval on the electrocardiogram;
very rarely venous thromboembolism.
From the hematopoiesis:
rarely - thrombocytopenia,
neutropenia, leukopenia, agranulocytosis.
On the part of the organs of vision:
often - a violation of accommodation, visual impairment;
infrequently - movement of eyeballs
From the respiratory system:
rarely - shortness of breath.
From the digestive system:
very often - dry mouth, increased salivation;
often - constipation, indigestion, nausea;
infrequently - vomiting, diarrhea.
Metabolic and nutritional disorders:
often - increased appetite, weight gain;
infrequent - loss of appetite, weight loss;
rarely - hyperglycemia, impaired glucose tolerance.
From the endocrine system:
rarely - hyperprolactinaemia.
From the urinary system:
infrequently urinary retention, painful urination.
On the part of the reproductive system:
infrequently - violations of ejaculation, erectile dysfunction;
rarely - gynecomastia, galactorrhea, amenorrhea.
Hepatic and hepatobiliary disorders:
infrequently - changes in laboratory parameters of liver function;
very rarely - jaundice.
From the immune system:
rarely - hypersensitivity, anaphylactic reactions.
Disturbances of the musculoskeletal system and connective tissue:
Often - myalgia;
infrequent muscle rigidity.
From the side of the skin and subcutaneous tissue:
often hyperhidrosis;
infrequently - skin rash, itching, photosensitivity, dermatitis.
On the part of the body as a whole:
often - asthenia, fatigue.
When taking neuroleptics, there is a possibility of developing a malignant neuroleptic syndrome (CNS). The main symptoms of the NSA are hyperthermia,Muscular rigidity and impaired consciousness in combination with dysfunction of the autonomic nervous system (labile arterial pressure, tachycardia, increased sweating). In addition to the immediate discontinuation of antipsychotics, the use of general supportive measures and symptomatic treatment is extremely important.
Patients on long-term care may develop tardive dyskinesia. Antiparkinsonian drugs do not eliminate its symptoms and can aggravate them. It is recommended to reduce the dose or, if possible, stop treatment with chlorprotixene.
With persistent akathisia, benzodiazepines may be useful, or propranolol.
When taking chlorprotixen, as with other neuroleptics, the following rare side effects were also observed: lengthening of the QT interval, ventricular arrhythmias - ventricular fibrillation, ventricular tachycardia, sudden death and pirouette ventricular tachycardia (Torsade de Pointes).
A sharp discontinuation of chlorprotrixen may be accompanied by the emergence of withdrawal reactions. The most common symptoms are nausea, vomiting, anorexia, diarrhea, rhinorrhea, sweating, myalgia, paresthesia, insomnia, nervousness, anxiety and agitation.Patients may also experience dizziness, an additional sensation of heat and cold and tremor. Symptoms usually begin within 1-4 days after cancellation and decrease within 7-14 days.